

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/028748-2021>

Contract

PF-07321332 Supply Agreement for Pandemic Purposes

Department of Health and Social Care

F03: Contract award notice

Notice identifier: 2021/S 000-028748

Procurement identifier (OCID): ocds-h6vhtk-02f7bb

Published 17 November 2021, 6:41pm

Section I: Contracting authority

I.1) Name and addresses

Department of Health and Social Care

39 Victoria Street

London

SW1H 0EU

Contact

Amy Watkins

Email

AntiviralsTaskforce@dhsc.gov.uk

Country

United Kingdom

NUTS code

UKI32 - Westminster

Internet address(es)

Main address

<https://www.gov.uk/government/organisations/department-of-health-and-social-care>

Buyer's address

<https://www.gov.uk/government/organisations/department-of-health-and-social-care>

I.4) Type of the contracting authority

Ministry or any other national or federal authority

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

PF-07321332 Supply Agreement for Pandemic Purposes

Reference number

C51900

II.1.2) Main CPV code

- 33600000 - Pharmaceutical products

II.1.3) Type of contract

Supplies

II.1.4) Short description

Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. So far there are no primary care antiviral drugs that can be easily dispensed specifically to treat SARS-CoV-2 and prevent its transmission in the community. This agreement is for the procurement of 250,000 units of PF-07321332/ritonavir. It is one of the first oral and direct-acting antiviral drugs globally and is part of the UK's multi-layered approach to COVID-19.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: 1 USD

II.2) Description

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

Main site or place of performance

London

II.2.4) Description of the procurement

Procurement of PF-07321332/ritonavir.

II.2.5) Award criteria

Price

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

- The services can be provided only by a particular economic operator for the following reason:
 - absence of competition for technical reasons
- Extreme urgency brought about by events unforeseeable for the contracting authority

Explanation:

Regulation 32(2)(c) The procurement was initiated on the basis that Regulation 32(2)(c) was applicable. In April 2021, the Antivirals Task Force (ATF) was established as it was recognised there was an urgent need to find alternative novel anti-viral treatments. As far as is strictly necessary: The use of antivirals was identified as strictly necessary for the cohort of individuals for whom a vaccine is not an option. There are genuine reasons for extreme urgency: The procurement of antivirals aims to protect vulnerable cohorts of the population. This risk of public health presents a genuine emergency. The events that have led to the need for extreme urgency were unforeseeable: There are many aspects of the COVID-19 pandemic, which have been entirely unforeseeable. DHSC is acting on the newest information it has available to tailor its COVID-19 response accordingly. The situation is not attributable to the contracting authority: The situation of extreme urgency is not attributable to DHSC. It is impossible to comply with the usual timescales in the PCR: When the need for antivirals was urgently identified in April 2021, DHSC conducted a comprehensive market review. The result of this exercise was that it became clear that a procurement exercise could not be run due to the absence of competition. If the ATF were to run a procurement process now, it would worsen DHSC's position. Regulation 32 (2) (b) (ii) In the course of this procurement, it has become clear to DHSC that Regulation 32(2)(b)(ii) is applicable. The antivirals market is inverted, with an imbalance between demand and supply and limited worldwide supply capacity. This means there will be a finite supply of antivirals available in 2021/22: to date only two antivirals have received or have the potential to gain MHRA approval for Autumn/Winter 2021. Looking forward, DHSC is expected to publish a Prior Information Notice (PIN) in November in respect of its likely further portfolio requirements with a view to running future open procurement exercises where possible. Please see Contracts Finder Notice for full justification.

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

18 October 2021

V.2.2) Information about tenders

Number of tenders received: 1

Number of tenders received from SMEs: 0

Number of tenders received from tenderers from other EU Member States: 0

Number of tenders received from tenderers from non-EU Member States: 0

Number of tenders received by electronic means: 0

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Pfizer Limited

Walton Oaks, Dorking Road

Kent

KT20 7NS

Country

United Kingdom

NUTS code

- UK - United Kingdom

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: 1 USD

Lowest offer: 1 USD / Highest offer: 1 USD taken into consideration

Section VI. Complementary information

VI.3) Additional information

Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors and (iii) impact fair competition between vendors.

VI.4) Procedures for review

VI.4.1) Review body

The High Court

Strand

London

WC2A 2LL

Email

generaloffice@administrativecourtoffice.justice.gov.uk

Country

United Kingdom

Internet address

<https://www.gov.uk/courts-tribunals>